Parexel's experts, along with select client partners, are presenting over 30 accepted abstracts through posters. These presentations showcase diverse research findings and outcomes that influence innovation, value, and healthcare decision-making.
View an overview of Parexel’s posters below. Please connect with our authors to find out more or visit us at the event at booth #1001.
ISPOR 2024 posters
Landscaping for product/therapy availability, positioning and reimbursement potential
Unlocking Equitable Access to Revolutionary Cell and Gene Therapies Across EU Member States
Do We Say “Game Over” When OS Data Is Not Mature at Launch? A Review of Value Drivers for Oncology Products in the Absence of Significant OS Gains
Characterizing Evidentiary Critiques in HTA Decision-Making for Treatments Indicated for Overweight and Obesity
A Comprehensive Evaluation of Clinical Studies in Digital Therapeutics: Uncovering Trends and Potential Implications
Evolving trends in HTAs individual and/or joint assessments and relevant collaborations
Landmark-Response Models: NICE in Theory, Not Submitted to NICE in Practice
A Case Study in PICO: What We Might Consider for JCA
For Orphan Drugs Technology Assessments, One Size May Not Fit All: Will the Implementation of JCA Lead to Increased Access or Will It Just Lead to a Duplication of Work?
JCA Is Just About the Corner: Is Spain Ready for It?
How Technology Will Play a Central Role in the Optimal Implementation of Joint Clinical Assessment (JCA) Across European Union (EU) in the Future?
Exploring the Impact of the New NICE Disease Severity Modifier on HTA Oncology Submissions: A Retrospective Analysis of Technology Appraisals
Are NICE Methods Appropriate for Rare Diseases That Do Not Meet the HST Criteria?
Long-term impact of new health policy initiatives on reimbursement and coverage
Analyzing the Impact of EU5 and UK Pricing Reforms: A Pathway to Adaptation in an Evolving Policy Landscape
Communication of clinical, economic, and real-world evidentiary differentiators
Do Subcutaneous Treatments Provide Most Cost Savings Than Intravenous Treatments in Breast Cancer: A Literature Review
Novel data analytics approaches to value demonstration and pricing strategies
Joint Survival Modeling in Rare Diseases: Validating Applicability and Considering Sample Size Challenges
Leveraging Response-Based Survival Observations From a Historical Trial to Extrapolate From Immature Data in a Study of Relapsed/Refractory Multiple Myeloma
Cost-Effectiveness Evaluation of Sequential Treatment Stategies for Treatment Naïve Patients With BRAF Mutant Metastatic Melanoma in UK: Nivolumab Plus Ipilimumab First-Line Versus Dabrafenib Plus Trametinib First-Line
Cognitive Assessments in Drug Development in Dementia and MCI: Clinical Trial Landscape Review and Recommendations for Future Neurodegenerative Studies
ePROVIDE Searches for Rare Disease Functioning and Epilepsy Measures in Children With KCNQ2
Beyond Always Treat: Dynamic Treatment Policies and Effect Estimates Using Real-World Data
Comparison of Novel Multilevel-Network Meta-Regression With Other Conventional Indirect Treatment Comparisons
Leveraging RWD to Advance Clinical Development: Statistical Considerations Related to External Control Arms
Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab Versus Other First-Line Therapies for Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer in Peru
Understanding Mortality Risk Among COVID-19 Vaccinated Individuals in the US: A Literature Review
Comparison of Survival Outcomes for [177Lu]Lu-PSMA-617 vs Other Systemic Treatments in Post-Taxane Metastatic Castration-Resistant Prostate Cancer Setting: A Bayesian Network Meta-Analysis
Artificial Intelligence (AI) use in data analysis, clinical development and HTAs processes
Can Artificial Intelligence Be Integrated to HTA Decision-Making? A Qualitative Discussion With Evidence Generation Experts
Revolutionizing Market Access: AI-Driven Pricing Strategies in the Pharmaceutical Industry
Assessing Efficiencies of AI-Powered Tools in Reporting Healthcare Economics and Outcomes Research (HEOR) Data for Health Technology Assessment (HTA) Submissions
Barriers Delaying the Implementation of Artificial Intelligence-Based Literature Reviews (AILRs) by Health Technology Assessment (HTA) Bodies
Use of Real-World Evidence or/and additional data to support reliable data generation to prove therapies efficacy or safety
Reducing Uncertainty in Post-Response Survival Estimates Using Bayesian Copula Models Informed by Historical Trial Data
A Real-World Evidence Study Describing Characteristics of Patients Receiving a CVD Risk Assessment in Primary Care in England Between 2013 and 2023
Supporting Decisions at the Interim Analysis for a Study in Advanced Cervical Cancer: An Application of Bayesian Dynamic Borrowing Survival Models Informed by Historical Trial Data
Separating Fact From Fiction: Potential Use of Post-Authorization Safety Studies to Assess Safety of GLP-1s in Obesity Treatment